Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 21419341 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Mendoza MC, et al. (2011) ERK-MAPK Drives Lamellipodia Protrusion by Activating the WAVE2 Regulatory Complex. Mol Cell 41, 661-71 21419341
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S183-p - Abi-1 (human) ▲
Orthologous residues
Abi‑1 (human): S183‑p, Abi‑1 iso2 (human): S178‑p, Abi‑1 iso3 (human): S183‑p, Abi‑1 (mouse): S183‑p, Abi‑1 iso4 (mouse): S178‑p, Abi‑1 (rat): S178‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mass spectrometry, mass spectrometry (in vitro), mutation of modification site, western blotting
 Relevant cell lines - cell types - tissues:  COS (fibroblast), HMEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
 Comments:  8A mutant (S183/S216/S225/T265/S267/S392/T394/S410A)
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  cell motility, altered, cytoskeletal reorganization
 Comments:  regulates WRC (WAVE2 regulatory complex) interaction with Arp2/3 and lamellipodial protrusion

S216-p - Abi-1 (human) ▲
Orthologous residues
Abi‑1 (human): S216‑p, Abi‑1 iso2 (human): S211‑p, Abi‑1 iso3 (human): S216‑p, Abi‑1 (mouse): S216‑p, Abi‑1 iso4 (mouse): S211‑p, Abi‑1 (rat): S211‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, western blotting
 Relevant cell lines - cell types - tissues:  COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  monkey
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
 Comments:  8A mutant (S183/S216/S225/T265/S267/S392/T394/S410A)
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  cell motility, altered, cytoskeletal reorganization
 Comments:  regulates WRC (WAVE2 regulatory complex) interaction with Arp2/3 and lamellipodial protrusion

S225-p - Abi-1 (human) ▲
Orthologous residues
Abi‑1 (human): S225‑p, Abi‑1 iso2 (human): S220‑p, Abi‑1 iso3 (human): S225‑p, Abi‑1 (mouse): S225‑p, Abi‑1 iso4 (mouse): S220‑p, Abi‑1 (rat): S220‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mass spectrometry, mass spectrometry (in vitro), mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial), COS (fibroblast), HMEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
 Comments:  8A mutant (S183/S216/S225/T265/S267/S392/T394/S410A)
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
U0126 EGF inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  cell motility, altered, cytoskeletal reorganization
 Comments:  regulates WRC (WAVE2 regulatory complex) interaction with Arp2/3 and lamellipodial protrusion

T265-p - Abi-1 (human) ▲
Orthologous residues
Abi‑1 (human): T265‑p, Abi‑1 iso2 (human): T260‑p, Abi‑1 iso3 (human): T265‑p, Abi‑1 (mouse): T265‑p, Abi‑1 iso4 (mouse): T260‑p, Abi‑1 (rat): T260‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, western blotting
 Relevant cell lines - cell types - tissues:  COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  monkey
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
 Comments:  8A mutant (S183/S216/S225/T265/S267/S392/T394/S410A)
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  cell motility, altered, cytoskeletal reorganization
 Comments:  regulates WRC (WAVE2 regulatory complex) interaction with Arp2/3 and lamellipodial protrusion

S267-p - Abi-1 (human) ▲
Orthologous residues
Abi‑1 (human): S267‑p, Abi‑1 iso2 (human): S262‑p, Abi‑1 iso3 (human): S267‑p, Abi‑1 (mouse): S267‑p, Abi‑1 iso4 (mouse): S262‑p, Abi‑1 (rat): S262‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, western blotting
 Relevant cell lines - cell types - tissues:  COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  monkey
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
 Comments:  8A mutant (S183/S216/S225/T265/S267/S392/T394/S410A)
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  cell motility, altered, cytoskeletal reorganization
 Comments:  regulates WRC (WAVE2 regulatory complex) interaction with Arp2/3 and lamellipodial protrusion

S392-p - Abi-1 (human) ▲
Orthologous residues
Abi‑1 (human): S392‑p, Abi‑1 iso2 (human): S330‑p, Abi‑1 iso3 (human): S336‑p, Abi‑1 (mouse): S365‑p, Abi‑1 iso4 (mouse): S359‑p, Abi‑1 (rat): S360‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, western blotting
 Relevant cell lines - cell types - tissues:  COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  monkey
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
 Comments:  8A mutant (S183/S216/S225/T265/S267/S392/T394/S410A)
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  cell motility, altered, cytoskeletal reorganization
 Comments:  regulates WRC (WAVE2 regulatory complex) interaction with Arp2/3 and lamellipodial protrusion

T394-p - Abi-1 (human) ▲
Orthologous residues
Abi‑1 (human): T394‑p, Abi‑1 iso2 (human): T332‑p, Abi‑1 iso3 (human): T338‑p, Abi‑1 (mouse): T367‑p, Abi‑1 iso4 (mouse): T361‑p, Abi‑1 (rat): T362‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, western blotting
 Relevant cell lines - cell types - tissues:  COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  monkey
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
 Comments:  8A mutant (S183/S216/S225/T265/S267/S392/T394/S410A)
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  cell motility, altered, cytoskeletal reorganization
 Comments:  regulates WRC (WAVE2 regulatory complex) interaction with Arp2/3 and lamellipodial protrusion

S410-p - Abi-1 (human) ▲
Orthologous residues
Abi‑1 (human): S410‑p, Abi‑1 iso2 (human): S348‑p, Abi‑1 iso3 (human): S354‑p, Abi‑1 (mouse): S383‑p, Abi‑1 iso4 (mouse): S377‑p, Abi‑1 (rat): S378‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, western blotting
 Relevant cell lines - cell types - tissues:  COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  monkey
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
 Comments:  8A mutant (S183/S216/S225/T265/S267/S392/T394/S410A)
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  cell motility, altered, cytoskeletal reorganization
 Comments:  regulates WRC (WAVE2 regulatory complex) interaction with Arp2/3 and lamellipodial protrusion

S296-p - WAVE2 (human) ▲
Orthologous residues
WAVE2 (human): S296‑p, WAVE2 (mouse): S296‑p, WAVE2 (rat): S296‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry, mass spectrometry (in vitro)
 Relevant cell lines - cell types - tissues:  HMEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE ERK2 (human)

S308-p - WAVE2 (human) ▲
Orthologous residues
WAVE2 (human): S308‑p, WAVE2 (mouse): S308‑p, WAVE2 (rat): S308‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mass spectrometry, mass spectrometry (in vitro), mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial), COS (fibroblast), HMEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE ERK2 (human)
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  cell motility, altered, cytoskeletal reorganization
 Comments:  regulates WRC (WAVE2 regulatory complex) interaction with Arp2/3 and lamellipodial protrusion

S343-p - WAVE2 (human) ▲
Orthologous residues
WAVE2 (human): S343‑p, WAVE2 (mouse): S341‑p, WAVE2 (rat): S341‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial), COS (fibroblast), HMEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
U0126 EGF inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  cell motility, altered, cytoskeletal reorganization
 Comments:  regulates WRC (WAVE2 regulatory complex) interaction with Arp2/3 and lamellipodial protrusion

T346-p - WAVE2 (human) ▲
Orthologous residues
WAVE2 (human): T346‑p, WAVE2 (mouse): T344‑p, WAVE2 (rat): T344‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial), COS (fibroblast), HMEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
U0126 EGF inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  cell motility, altered, cytoskeletal reorganization
 Comments:  regulates WRC (WAVE2 regulatory complex) interaction with Arp2/3 and lamellipodial protrusion

S351-p - WAVE2 (human) ▲
Orthologous residues
WAVE2 (human): S351‑p, WAVE2 (mouse): S349‑p, WAVE2 (rat): S349‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial), COS (fibroblast), HMEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
U0126 EGF inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  cell motility, altered, cytoskeletal reorganization
 Comments:  regulates WRC (WAVE2 regulatory complex) interaction with Arp2/3 and lamellipodial protrusion


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.